Navigation Links
ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses

ADVENTRX Presents Results at International Conference on Antiviral Research

SAN DIEGO, May 03, 2007 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. , a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that it presented results demonstrating synergistic activity against human and avian influenza (bird flu) viruses when the Company's broad-spectrum antiviral drug candidate, ANX-201 (thiophosphonoformic acid), was combined with oseltamivir phosphate (Tamiflu(R)) in preclinical tests. ANX-201 also demonstrated single agent antiviral activity against these viruses. The results were presented at the International Conference on Antiviral Research (ICAR) in Palm Springs, CA on Wednesday, May 2nd.

"These results suggest we can simultaneously improve efficacy and lower dosages with a two drug regimen of ANX-201 and Tamiflu," said Evan M. Levine, chief executive officer of ADVENTRX. "We intend to continue to investigate the use of ANX-201 in avian flu."

As a single agent, ANX-201 showed dose-dependent antiviral activity against human, equine and avian influenza virus. Fixed-dose combinations of ANX-201 and the neuraminidase inhibitor Tamiflu produced a supra-additive, or synergistic, antiviral activity against the human and avian influenza viruses, as demonstrated by an overall lowering of the drug concentrations required to achieve virus inhibition. ANX-201 dosage could be reduced up to 10 fold against human influenza strains H3N2 and H1N1, and up to 100 fold against avian influenza strain H5N2 when administered in combination with Tamiflu. Tests were performed in vitro using standard cell-based influenza infectivity assays. A copy of the poster presentation is available for download from the "Resources" section of the Company's web site at




Page: 1 2 3

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
3. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
4. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
5. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
6. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
7. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
8. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
9. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
10. King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For 24-hour Blood Pressure Control
11. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines

Post Your Comments:
(Date:12/3/2009)...ALAMAZOO, Mich., Dec. 3 ... that its Board of Directors has authorized the Co...on stock. The manner, timing and amount of any pu...ment based on their evaluation of market condition...ct to regulatory considerations. Purchases may be...
(Date:12/3/2009)..., CAMBRIDGE, Mass., Dec. 3, 2009 R...y of Raytheon Company (NYSE: RTN ), has licensed...raphy (SDM) technology to FUJIFILM Corp. ,, FU...h the Aspire HD FFDM system. Combined with SDM tec...will deliver stereo images for 3-D viewing. FUJIFI...
(Date:12/3/2009)...ARRISBURG, Pa., Dec. 3 ...ple processing company build a new cold storage fa...ributor expand operations while creating at least ...y. ,, The Pennsylvania Industrial Development A... for three projects. The investments, in the form ...
Breaking Medicine Technology:Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend 2Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation 2Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation 3Governor Rendell: New State Investments Bear Fruit in Adams County; Help Pharmaceutical Company Expand in Philadelphia 2Childhood ADHD Linked to Criminal Behavior in Adults 59767 1Childhood ADHD Linked to Criminal Behavior in Adults 59767 2Mercury Levels Not Abnormal in Autistic Children 59764 1Mercury Levels Not Abnormal in Autistic Children 59764 2Mercury Levels Not Abnormal in Autistic Children 59764 3Detecting the undetectable in prostate cancer screening 59761 1Detecting the undetectable in prostate cancer screening 59761 2Detecting the undetectable in prostate cancer screening 59761 3Detecting the undetectable in prostate cancer screening 59761 4
...th pancreatic,cancer recently became the first per...g Elekta VMAT (Volumetric intensity Modulated Arc ...is revolutionary new technology,dramatically decre...o the,tumor target without compromising coverage a...m/cgi-bin/prnh/20020318/ELEKTALOGO ), From the p...
...(AIM: SLN), a,leading European RNAi focused biotec... Quark Pharmaceuticals Inc. ("Quark") together wit...with RTP-801i-14 (PF-4523655), a small,interfering...s AtuRNAi,technology. Its initiation triggers a $1...., The study is designed to evaluate the effectiv...
Other Medicine Technology:Seattle's Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT 2Seattle's Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT 3Seattle's Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT 4Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial 2Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial 3Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial 4
(Date:12/3/2009)... Mass., Dec. 3 The Cancer Center...first patients, Harrington Hospital announced toda...iately," said Diane Becquart, Director of The Canc...anted today by the Massachusetts Department of Pub...f the facility. ,, The opening of The Cancer C...
(Date:12/3/2009)...GTON, Dec. 3 Today the ...the Senate health care bill by a vote of 61-39. T...coverage, but it also fails to explicitly exclude...ation (HRSA) could categorize abortion as "prevent...for abortion by all private plans. The recommenda...
(Date:12/3/2009)...LLS, Calif., Dec. 3 Christian Audi...ign Gala and Premier Shopping Event for Project An... off regular prices. The event kicks off on Thurs...7, 2009, located at 9900 Wilshire Boulevard (forme...ease visit www.divinedesign.org for more informa...
(Date:12/3/2009)...eeks and includes minimally invasive procedures, s...ay News) -- Potentially fatal blood clots after su...been thought, a British study finds. , "What is..., but that it lasts much longer than people have t...ogist at the University of Oxford and a leader of ...
(Date:12/3/2009)...tim often play out at school and home, study finds...- School bullies are also likely to bully their br...n study that included 195 children between the age...a sibling no more than four years older or younger...ere bullied at school or at home. The findings wer...
Breaking Medicine News(10 mins):Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Americans United For Life: Senate Passes the Pro-Abortion Mikulski Amendment Under the Guise of 'Preventive Care' 2Health News:Christian Audigier Represented at Divine Design for Project Angel Food 2Health News:Blood Clot Threat After Surgery Worse Than Thought 2Health News:Blood Clot Threat After Surgery Worse Than Thought 3Health News:Bullies May Intimidate Siblings, Too 2
...iticalPoint, LLC, proudly announce positive result...Pharmacy Purchasing and Products 2nd annual nation...poration announces the positive customer satisfact...ities surveyed by Pharmacy Purchasing and Product...
...offers a convenient option that may help patients ...hile decreasing patient pill burden(1) , , PARSIP...ounced that the United States Food and Drug Admini...ely to need multiple antihypertensive agents to ac...
...wing How Restrictive Gene Patents Hurt Women , , ... Girard underwent genetic testing to determine whe...uld have her ovaries removed. But the test didn,t ... holds the patents on the genes associated with br...
...., May 13 The coverage of Human Swine Flu H1N1 is...orldNet.com ) provides a one-stop shop for healt...o, HealthWorldNet.com (HWN) is the fastest-growing...nd medicine in addition to providing edgy, enterta...
... MPX 46 Watts Enables Physicians to Melt and Remov...tient Safety , , WESTFORD, Mass., May 13 Cynos... and manufacturer of a broad array of light-based ...imed Smartlipo platform of minimally invasive work...
... May 5th, the World Health Organization launched a...r Hands ( http://www.who.int/gpsc/5may/en/index...d Infections than car accidents, breast cancer and... billion. The CDC estimates that at least half of ...
Other Medicine News:Health News:CriticalPoint(TM) Training Rated 'Excellent' in Customer Satisfaction 2Health News:CriticalPoint(TM) Training Rated 'Excellent' in Customer Satisfaction 3Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 2Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 3Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 4Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 5Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 6Health News:Video: Liberate The Breast Cancer Genes 2Health News:Video: Liberate The Breast Cancer Genes 3Health News:HealthWorldNet.com Announces HealthWiNs Awards 2Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 2Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 3Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 4Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 5Health News:Monitoring System Stops Hospital Infections with Traffic Light Camera to Capture Hand Hygiene Violators 2Health News:Monitoring System Stops Hospital Infections with Traffic Light Camera to Capture Hand Hygiene Violators 3
Eftiar®-Octane
Robinson Clear Vinyl Urethral Catheters (100% Latex Free)
CURITY ULTRAMER Urethral Red Rubber Catheters (Latex)
DOVER Silver Foley Catheter 3-way
Medicine Products: